398 related articles for article (PubMed ID: 23993401)
1. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
Jain S; Poon I; Soliman H; Keller B; Kim A; Lochray F; Yeung L; Cheung P
Radiother Oncol; 2013 Aug; 108(2):320-5. PubMed ID: 23993401
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
3. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.
van der Voort van Zyp NC; Prévost JB; van der Holt B; Braat C; van Klaveren RJ; Pattynama PM; Levendag PC; Nuyttens JJ
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):31-7. PubMed ID: 19864077
[TBL] [Abstract][Full Text] [Related]
5. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
6. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
8. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
9. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
12. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
14. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
15. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
16. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
18. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
20. Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?
Paludan M; Traberg Hansen A; Petersen J; Grau C; Høyer M
Acta Oncol; 2006; 45(7):818-22. PubMed ID: 16982545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
